Posts Tagged ‘obesity’

On the opening day of ObesityWeek yesterday, we got quite a treat in a passionate debate of the Lancet Commission report on clinical obesity. Four of our favorite people – Sue Yanovski, Bob Kushner, Fatima Cody Stanford, and Donna Ryan – participated and made it memorable. We walked away with a clear understanding that many […]

It was remarkable and much needed. On the pre-convention day for ObesityWeek in Atlanta, ADA, OAC, and TOS began work to collaborate on models for obesity care that will begin to deliver on a scale that matches the urgency and scope of unmet medical need. TOS Vice-President Jonathan Purnell described the urgency of this to […]

A year ago, we had these wonderful new obesity medicines – semaglutide and tirzepatide – and nobody could get them. Demand had outstripped supply and we had a shortage. Earlier this year, the supply shortage for both drugs resolved, but now we face the same situation because of a different shortage. There is a shortage […]

The headlines won’t stop. “Obesity rates are falling and it’s almost certainly because of Ozempic,” says the Futurism banner. Vox tells us “the Ozempic effect is finally showing up in obesity data.” So can it be true that use of GLP-1s is lowering obesity prevalence? The short answer is no. Not now. Probably not ever. […]

We’re packing our bags and scanning the meeting app for ObesityWeek in Atlanta, November 4-7. This promises to be a very intense week, with the biggest attendance yet for this signature meeting of the Obesity Society. The agenda for the week has a lot of options and we are still processing them all. But for […]

Very often, news reports about obesity rates have more puffery than substance to offer. However, a report this week from Gallup deserves your attention. It tells us that a steady decline in self-reported obesity rates appears to be a genuine trend and that an association with use of GLP-1s may explain it. In fact, for […]

In two decades of advocacy for persons living with obesity, we have found great satisfaction in seeing a central role emerge for the lived experience of these people. But it is especially inspiring to see it spread across many different countries with many different health systems. We saw this up close yesterday as a keynote […]

A new study in Lancet tells us that we need a fundamental reframing of the medical benefits semaglutide can bring to a growing number of people around the world. In the simplest terms, researchers have found that the heart benefits of semaglutide actually have relatively little to do with weight loss. Professor John Deanfield was […]

There are those who would tell us that the phenomenon of food noise lives only in the heads of people who find it distressing. Philosopher Kate Manne wants to turn it into a Gaslight phenomenon, telling us to “dance to it.” Philosophize it away. But with a new and rigorous validation of the RAID-FN scale, […]

We are most accustomed to technology bringing economic disruption. Three decades ago, it was the internet. Then smartphones and social media. Now, we obsess about the effects of artificial intelligence. But a strong case is building that obesity medicine is becoming an economic disruptor on a scale that is equal or greater than any of […]